Trombosis venosa retiniana: mucho trabajo por hacer / Retinal vein thrombosis: a lot of work to do

No disponible

Resultados del tratamiento médico de la embolia de pulmón en una unidad de corta estancia de un hospital de tercer nivel: ¿es el lugar adecuado? / Results of pulmonary embolism treatment in a tertiary hospital short stay unit. Is this the right place?

Objetivo. Describir la estancia media (EM) de la embolia de pulmón (EP) en una unidad de trombosis (UT) dependiente de una unidad de corta estancia (UCE) de un hospital de tercer nivel. Comparar estos datos con el resto de hospitales de nuestra región, con los del resto de comunidades autónomas (CCAA) y con el mismo hospital durante un año previo a nuestra existencia. Material y método. Estudio observacional retrospectivo descriptivo en el que se incluyeron los pacientes con diagnóstico de EP en el Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA) durante el año 2012. Clasificamos estos datos por servicio hospitalario, calculando la EM. Comparamos esta con la del resto de hospitales de nuestra región, con el resto de CCAA y con nuestros datos en el año 2007, cuando no existía aun la UT. Resultados. Se incluyeron 113 pacientes: 60 (53%) ingresaron en la UT, siendo la EM de 4,39 días, en Oncología, de 7,45, y en Medicina Interna (MI), de 15,38. No hubo ningún fallecido en la UT y solo se produjeron 3 reingresos (5%). Los datos publicados mostraron que la EM en todos los hospitales de nuestra región fue de 8,25 días; en nuestro hospital fue de 5,18 días y en el resto de hospitales, mayor. La CCAA con mejor EM fue el País Vasco con 6,85 días. En el año 2007, hubo 70 pacientes con EP en el HCUVA: 34 (49%) en MI con una EM de 8,50 días, 11 (31%) en Oncología con una EM de 9,64 días y 3 (4,3%) en Neumología, con una EM de 19 días; la mortalidad global fue del 11% y la tasa de reingresos en MI, del 6%. Conclusión. La EM de la EP en la UT en una UCE fue menor que en el resto de servicios de nuestro hospital, menor que en el resto de hospitales de nuestra comunidad, menor que en el resto de CCAA y menor que en cualquier servicio de nuestro hospital en una época anterior a nuestra existencia, sin aumentar la tasa de reingreso ni la mortalidad (AU)

Objectives. To determine the mean stay (MS) of patients with pulmonary embolism (PE) in a thrombosis unit (TU) with a short stay unit (SSU) in a tertiary hospital. To compare the data collected with those of other hospitals in the same region, of other regions (Autonomous Communities [AACC]), and within the same hospital in the year before the SSU opened. Material and methods. A descriptive retrospective observational study that included patients with a diagnosis of PE in the University Hospital Virgen de la Arrixaca (HCUVA) in 2012. These data were classified by hospital department, and used for calculating the mean stay. This was then compared with that of other hospitals in our region, with the rest of the regions, and with the data in 2007 (the last year without a TU). Results. A total of 113 patients with PE were included, 60 (53%) in the TU with an MS of 4.39, in Oncology, 7.45, and Internal Medicine (IM), 15.38 days. There were no deaths in the TU and only 3 (5%) readmissions. Published data showed that the MS in all hospitals in our region was 8.25, 5.18 in our hospital, and higher in the rest of hospitals. The best AACC was the Basque Country with an MS of 6.85 days. In 2007, there were 70 patients with PE in the HCUVA, 34 (49%) in IM, with an MS of 8.50, Oncology 11 (31%) with an MS 9.64, and Chest Diseases 3 (4.3%) with an MS 19 days, and with an overall mortality of 11% and a rate of readmissions in IM of 6%. Conclusion. The mean stay for a PE in the SSU of a TU was lower than in the rest of the hospital departments, lower than the rest hospitals of our region, lower than the rest of the regions, and lower than any department of our hospital before the SSU existed, without increasing the readmission or mortality rate (AU)

Queilitis comisural como forma de presentación de una leishmaniasis cutánea crónica / Chronic cutaneous leishmaniasis presenting as commissural cheilitis

No disponible

[Results of pulmonary embolism treatment in a tertiary hospital short stay unit. Is this the right place?]. / Resultados del tratamiento médico de la embolia de pulmón en una unidad de corta estancia de un hospital de tercer nivel: ¿es el lugar adecuado?

OBJECTIVES: To determine the mean stay (MS) of patients with pulmonary embolism (PE) in a thrombosis unit (TU) with a short stay unit (SSU) in a tertiary hospital. To compare the data collected with those of other hospitals in the same region, of other regions (Autonomous Communities [AACC]), and within the same hospital in the year before the SSU opened. MATERIAL AND METHODS: A descriptive retrospective observational study that included patients with a diagnosis of PE in the University Hospital Virgen de la Arrixaca (HCUVA) in 2012. These data were classified by hospital department, and used for calculating the mean stay. This was then compared with that of other hospitals in our region, with the rest of the regions, and with the data in 2007 (the last year without a TU). RESULTS: A total of 113patients with PE were included, 60 (53%) in the TU with an MS of 4.39, in Oncology, 7.45, and Internal Medicine (IM), 15.38days. There were no deaths in the TU and only 3 (5%) readmissions. Published data showed that the MS in all hospitals in our region was 8.25, 5.18 in our hospital, and higher in the rest of hospitals. The best AACC was the Basque Country with an MS of 6.85days. In 2007, there were 70patients with PE in the HCUVA, 34 (49%) in IM, with an MS of 8.50, Oncology 11 (31%) with an MS 9.64, and Chest Diseases 3 (4.3%) with an MS 19days, and with an overall mortality of 11% and a rate of readmissions in IM of 6%. CONCLUSION: The mean stay for a PE in the SSU of a TU was lower than in the rest of the hospital departments, lower than the rest hospitals of our region, lower than the rest of the regions, and lower than any department of our hospital before the SSU existed, without increasing the readmission or mortality rate.

Fusión de 2 costillas como causa de trombosis venosa profunda de miembro superior / Fusion of 2 ribs as the cause of deep vein thrombosis in the arm

No disponible

A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity.

BACKGROUND: No studies have identified which patients with upper-extremity deep vein thrombosis (DVT) are at low risk for adverse events within the first week of therapy. METHODS: We used data from Registro Informatizado de la Enfermedad TromboEmbólica to explore in patients with upper-extremity DVT a prognostic score that correctly identified patients with lower limb DVT at low risk for pulmonary embolism, major bleeding, or death within the first week. RESULTS: As of December 2014, 1135 outpatients with upper-extremity DVT were recruited. Of these, 515 (45%) were treated at home. During the first week, three patients (0.26%) experienced pulmonary embolism, two (0.18%) had major bleeding, and four (0.35%) died. We assigned 1 point to patients with chronic heart failure, creatinine clearance levels 30-60 mL min(-1) , recent bleeding, abnormal platelet count, recent immobility, or cancer without metastases; 2 points to those with metastatic cancer; and 3 points to those with creatinine clearance levels < 30 mL min(-1) . Overall, 759 (67%) patients scored ≤ 1 point and were considered to be at low risk. The rate of the composite outcome within the first week was 0.26% (95% confidence interval [CI] 0.004-0.87) in patients at low risk and 1.86% (95% CI 0.81-3.68) in the remaining patients. C-statistics was 0.73 (95% CI 0.57-0.88). Net reclassification improvement was 22%, and integrated discrimination improvement was 0.0055. CONCLUSIONS: Using six easily available variables, we identified outpatients with upper-extremity DVT at low risk for adverse events within the first week. These data may help to safely treat more patients at home.

Rhabdomyolysis after initial session of indoor cycling: analysis of 11 patients.

AIM: The aim of this paper was to highlight the special frequency of cases of rhabdomyolysis related to the practice of indoor cycling and to define the characteristics, course, and outcome of this disease. METHODS: Retrospective review of clinical histories of patients diagnosed with rhabdomyolysis after indoor cycling in our unit from January 2012 to April 2013. RESULTS: Eleven patients were analyzed. All patients, regardless of the degree of previous physical training, were diagnosed after a first session of indoor cycling. Mean age was 27.63 years (SD=5.74). Fifty-four percent were women. Creatine kinase (CK) levels gradually decreased in response to rest and intensive intravenous hydration. Only in two cases was renal failure observed, and in none were electrolyte disorders, disseminated intravascular coagulation (DIC) or compartmental syndrome detected. CONCLUSION: A first session of indoor cycling has become a common cause of rhabdomyolysis secondary to the physical exercise in recent years, which should alert those responsible for teaching this sport of the need for a gradual start under adequate hydration and environmental conditions, because although the condition has a benign course with adequate treatment and the complication rate is low, there are patients with increased susceptibility to very high CK blood levels requiring hospitalization for treatment and follow-up of possible complications.

[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? No]. / Novedades en anticoagulación. Nos olvidamos ya de la heparina y las antivitaminas K? No.

The boost given to the new anticoagulants by the results of clinical trials is beginning to jeopardize the hegemony of coumadin and heparin therapy, the cornerstone of anticoagulation in the last 50 years. The safety and effectiveness of this new drug family with respect to warfarin and low-molecular weight heparin in the different facets of anticoagulation has been demonstrated, both in prophylaxis (total hip and knee replacement) and in treatment (atrial fibrillation and venous thromboembolic disease). These agents seem to offer superior convenience compared with their predecessors, although it is not clear whether this translates into greater treatment adherence when the data are analyzed in depth. Another drawback of these agents is their price, a consideration of major importance in the last few years, and which would only be offset by savings in the cost of the routine blood monitoring required for coumadin agents, available in hospitals. Finally, the populations excluded from the clinical trials should not be forgotten, as they are the last obstacle to be overcome and the basis for justifying the maintenance of heparin or coumadin therapy, depending on the case. The present article provides a more detailed analysis of these arguments, which serve as the basis for a reflection on the early retirement of classical anticoagulants.

Novedades en anticoagulación. ¿Nos olvidamos ya de la heparina y las antivitaminas K? No / New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? No

El empuje de los nuevos anticoagulantes con la aparición de los resultados de sus ensayos clínicos, está empezando a cuestionar la hegemonía de los dicumarínicos y la heparina en el mundo de la anticoagulación de los últimos cincuenta años. Esta nueva familia de fármacos ha demostrado seguridad y eficacia respecto a la warfarina y las heparinas de bajo peso molecular en las distintas facetas de la anticoagulación, tanto en la profilaxis (prótesis de cadera y rodilla) como en el tratamiento (fibrilación auricular y enfermedad tromboembólica venosa). En cuanto a la comodidad, se le presupone superioridad respecto a sus predecesores, aunque no queda demostrado que eso se traduzca en adhesión al tratamiento cuando analizamos los datos profundamente. Otro inconveniente de estos tratamientos es el precio, faceta de gran importancia en los últimos años y que sólo resultaría rentable si lo comparamos con el gasto que supone la consulta especializada de control de rango de anticoagulación con los dicumarínicos, existente en los hospitales. Por último, no podemos olvidar todas las poblaciones que fueron excluidas de los ensayos clínicos, que serían el bastión más difícil de rebasar por parte de los nuevos anticoagulantes y la piedra angular para justificar el mantenimiento de la heparina o los dicumarínicos según el caso. En este artículo realizamos un análisis más detallado de estos argumentos para hacer una reflexión en voz alta sobre la jubilación anticipada de los clásicos de la anticoagulación (AU)

The boost given to the new anticoagulants by the results of clinical trials is beginning to jeopardize the hegemony of coumadin and heparin therapy, the corner stone of anticoagulation in the last 50 years. The safety and effectiveness of this new drug family with respect to warfarin and low-molecular weight heparin in the different facets of anticoagulation has been demonstrated, both in prophylaxis (total hip and knee replacement) and in treatment (atrial fibrillation and venous thromboembolic disease). These agents seem to offer superior convenience compared with their predecessors, although it is not clear whether this translates into greater treatment adherence when the data are analyzed in depth. Another drawback of these agents is their price, a consideration of major importance in the last few years, and which would only be offset by savings in the cost of the routine blood monitoring required for coumadin agents, available in hospitals. Finally, the populations excluded from the clinical trials should not be forgotten, as they are the last obstacle to be overcome and the basis for justifying the maintenance of heparin or coumadin therapy, depending on the case. The present article provides a more detailed analysis of these arguments, which serve as the basis for a reflection on the early retirement of classical anticoagulants (AU)

Varón de 63 años con hemoptisis, dolor pleurítico y masa pulmonar / A 63-year-old male with hemoptysis, pleuritic pain, and lung mass

No disponible

Mujer asmática con nódulos dolorosos en ambos brazos / Asthmatic woman with painful nodules on both arms

No disponible